Immunoglobulin-mediated membranoproliferative glomerulonephritis
MONDO:0014005Glomerulonephritis characterized by mesangial proliferation, endocapillary proliferation, and glomerular capillary wall remodeling with immune complex deposits from classical complement pathway activation.
Also known as: Ig-mediated MPGN, Ig-mediated membranoproliferative glomerulonephritis, NPHS7, immune complex mediated membranoproliferative glomerulonephritis, immunoglobulin-mediated MPGN, immunoglobulin-mediated membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis type I, mesangiocapillary glomerulonephritis type 1
16 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Can a gene-silencing drug calm overactive complement in kidney disease?
Disease control Not yet recruitingThis phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
A simple blood test may reveal kidney damage in lupus — no biopsy needed?
Diagnosis Not yet recruitingThis study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC